At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02142 HBM HOLDINGS-B
Closed 03-24 16:08:20
11.700
+0.520
+4.65%
High11.790Low11.280Vol2.91M
Open11.570D1 Closing11.180Amplitude4.56%
Mkt Cap10.18BTradable Cap10.18BTotal Shares870.00M
T/O33.73MT/O Rate0.33%Tradable Shares870.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hong Kong Stocks Surge as TSLP Antibody Therapy Phase I Trial Results Published
Stock News  ·  15:06
Hong Kong Stocks Surge as TSLP Antibody Therapy Phase I Trial Results Published
Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults
Reuters  ·  03-23 11:15
Harbour BioMed publishes Phase I results for TSLP antibody HBM9378 in 50 healthy adults
Harbour BioMed appoints Jenny Xie as chief scientific officer for immunology
Reuters  ·  03-19
Harbour BioMed appoints Jenny Xie as chief scientific officer for immunology
Harbour Biomed Appoints DR. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
THOMSON REUTERS  ·  03-19
Harbour Biomed Appoints DR. Jenny Xie as Chief Scientific Officer, Immunology and Head of Global External Innovation
HBM Holdings-B (02142) Schedules 30 March 2026 Board Meeting to Approve FY 2025 Results
Bulletin Express  ·  03-18
HBM Holdings-B (02142) Schedules 30 March 2026 Board Meeting to Approve FY 2025 Results
HBM Holdings schedules board meeting to approve annual results for 2025
Reuters  ·  03-18
HBM Holdings schedules board meeting to approve annual results for 2025
HBM HOLDINGS-B Sees Shares Plunge Over 40% in 5 Months: Is BD Good News a "Sell Signal"?
Stock News  ·  03-15
HBM HOLDINGS-B Sees Shares Plunge Over 40% in 5 Months: Is BD Good News a "Sell Signal"?
HBM Holdings (SEHK:2142) Valuation Check After Recent Share Price Rebound
Simply Wall St.  ·  03-11
HBM Holdings (SEHK:2142) Valuation Check After Recent Share Price Rebound
BUZZ-Sichuan Kelun-Biotech jumps most in near 12 months on drug application
Reuters  ·  03-10
BUZZ-Sichuan Kelun-Biotech jumps most in near 12 months on drug application
Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares
Stock News  ·  03-10
Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares
HBM Holdings Gets China IND Approval for Atopic Dermatitis Drug Candidate
MT Newswires Live  ·  03-09
HBM Holdings Gets China IND Approval for Atopic Dermatitis Drug Candidate
HBM Holdings-B (02142) Receives NMPA IND Approval for Long-Acting Bispecific Antibody HBM7575 Targeting Atopic Dermatitis
Bulletin Express  ·  03-09
HBM Holdings-B (02142) Receives NMPA IND Approval for Long-Acting Bispecific Antibody HBM7575 Targeting Atopic Dermatitis
HBM HOLDINGS-B Secures Regulatory Nod for Atopic Dermatitis Treatment Trial
Stock News  ·  03-09
HBM HOLDINGS-B Secures Regulatory Nod for Atopic Dermatitis Treatment Trial
China NMPA approves Kelun-Biotech IND for SKB575 in atopic dermatitis
Reuters  ·  03-09
China NMPA approves Kelun-Biotech IND for SKB575 in atopic dermatitis
Hbm Holdings - Nmpa Approves Investigational New Drugapplication for Hbm7575 (Skb575) for Atopic Dermatitis
THOMSON REUTERS  ·  03-09
Hbm Holdings - Nmpa Approves Investigational New Drugapplication for Hbm7575 (Skb575) for Atopic Dermatitis
HBM HOLDINGS-B (02142) Announces February 2026 Monthly Return Highlights
Bulletin Express  ·  03-05
HBM HOLDINGS-B (02142) Announces February 2026 Monthly Return Highlights
Zhongtai Securities Reiterates "Buy" on HBM HOLDINGS-B (02142) Following Heavy-Chain Antibody HBM4003 Out-Licensing Deal
Stock News  ·  02-27
Zhongtai Securities Reiterates "Buy" on HBM HOLDINGS-B (02142) Following Heavy-Chain Antibody HBM4003 Out-Licensing Deal
HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China
Simply Wall St.  ·  02-24
HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China
BUZZ-HK-listed HBM jumps on licensing deal with Solstice on oncology drug
Reuters  ·  02-23
BUZZ-HK-listed HBM jumps on licensing deal with Solstice on oncology drug
HBM HOLDINGS-B Shares Surge Over 8% in Morning Session on Major Global Licensing Deal for Next-Generation Antibody
Stock News  ·  02-23
HBM HOLDINGS-B Shares Surge Over 8% in Morning Session on Major Global Licensing Deal for Next-Generation Antibody

Introduction

Company Name.
HBM HOLDINGS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
Issue price:
--